Guangdong has reduced the price of 8677 varieties of medicines 8 times in two years

In Guangdong, the price of drug price reductions for eight times in two years accumulated to exceed 4 billion yuan. It was learned from the Guangdong Provincial Price Bureau that Guangdong has reduced the total price of medicines for a total of 8677 varieties in eight years in the past two years based on the cost of drugs and the actual sales price in the market. The price reduction rate reached 20%, and the accumulated price reduction amounted to more than 4 billion yuan.

The Guangdong Provincial Price Bureau and the Guangdong Pharmaceutical Price Association jointly organized the third “Guangdong Pharmaceutical Price Reform Forum” on the 25th to focus on the medical price management under the new medical reform background, and promote the use of price levers in order to promote reform of public hospitals and consolidate the basic drug system. Assisting the reform of the medical and health system, improving people's livelihood, and promoting the development of the pharmaceutical industry.

The reporter learned from the forum that in recent years, Guangdong has focused on the reform of the medical and health system, promoted the elimination of drug additions and established pilot reforms for the reform of medical institutions' compensation mechanisms, implemented "differential pricing" for drugs, and implemented differentiated pricing policies according to the quality of medicines. Drug R&D innovation and enterprise quality improvement; development of a list of low-priced drugs for essential drugs to promote the production and supply of high-quality cheap drugs.

In addition, Guangdong also fully implements the “three-control” policy for drugs, which imposes upper-limit control on the maximum retail price, supply price, and circulation rate of drugs, and promotes the conversion of low-priced drug production and pharmaceutical companies’ “subsidiary underwriting” sales model. From January to July last year, the proportion of drug purchases with a unit price of less than 40 yuan increased by 14.6% year-on-year, and the unit price of 200 yuan or more to 600 yuan (inclusive) and 600 yuan or more to 2,000 yuan (inclusive) decreased 4.5% and 6.5%, respectively. For the patient to reduce the burden.

Representatives from the National Development and Reform Commission's Price Division, the Guangdong Provincial Medical Reform Office, the Department of Human Resources and Social Security and other related departments, and domestic experts in the field of well-known medical reforms attended the forum.

News Links: "Daily List of Guangdong Drug Price Management Analysis"

In January 2012, the Guangdong Provincial Price Bureau issued three notifications on drug price management, which were “Notice on Printing and Distributing the Catalogue of the Newly Approved Price-Controlled Drugs for the Second Batch of New Government in Guangdong Province” and “Publishing Ceftimezime and Other Drugs Highest. The "Retail price notification" and "Notice on the publication of the highest retail price of gentamicin and other drugs" involved more than 600 kinds of drugs in total. The introduction of three drug price management notifications within one month is also rare in other parts of the country. Each of the three notifications has its own priorities, and the Circular on Printing and Distributing the Catalogue of the Newly Added Government's Maximum Price-restricted Drugs in Guangdong Province mainly focuses on new clinical drugs; the Notice on the Promulgation of the Maximum Retail Prices of Cefixime and Other Drugs More attention was paid to the commonly used antibiotics for hospitals and commonly used drugs for chronic diseases; the “Notice on the publication of the highest retail prices of gentamicin and other drugs” was mainly OTC. The following brief analysis of each notification:

The Notice on Printing and Distributing the Catalogue of the Second Batch of Newly Added Governmental Price-Restricted Drugs in Guangdong Province imposes a ceiling price control on 442 drugs. This is the excluding of 480 prescription drugs included in the government's price-restricted management in September 2009. After the second batch of new drugs. There are 199 kinds of chemical drugs and 243 kinds of proprietary Chinese medicines, including antibiotics, cardiovascular disease, diabetes and anti-tumor drugs according to the type of drugs. Drugs that are more common in retail pharmacies such as sildenafil (trade name: Viagra, commonly known as Viagra), sibutramine (a diet pill, more famously known as “Qumei”), and drugs such as Qinggan Lidan Capsule are also included. . Clinically proven new drugs with proven curative effects have entered the list this time. For example, new product monoclonal antibodies that are popular in clinical practice in recent years have been included in this new catalog, namely trastuzumab and cetuximab. Anti-nilotuzumab.

The "Notice on the publication of the highest retail prices of gentamycin and other drugs" involved 99 drugs, a total of 435 specifications formulations, most of which are chemical drugs, only one proprietary Chinese medicine. The list of non-prescription drugs (OTCs) is the main list of notifications. Out of 435 dosage forms, 375 are non-prescription drugs, accounting for more than 86%. The medicine list includes many analgesics, cold medicines and topical dermatological medicines. Pain medications include ibuprofen (the more well-known products are "Fenbid"), acetaminophen, naproxen and others. Cold medicines include bisecting pseudoephedrine, ammoniacal pseudoephedrine, and ammonia golden sensitive. Dermatological drugs for external use include ketoconazole (cream), econazole (cream), hydrocortisone butyrate (ointment), and the like.

The Notice on the Promulgation of the Maximum Retail Price of Pharmaceuticals such as Cefixime was related to 115 drugs, with a total of 200 specifications, of which 76 were chemical drugs and 39 were proprietary Chinese medicines. Chemical drugs are classified by category, mainly anti-infective drugs, high blood pressure drugs, and diabetes drugs. Anti-infective drugs include cefixime, amoxicillin clavulanic acid, roxithromycin, cefuroxime and the like. Drugs for the treatment of hypertension include nifedipine, amlodipine, irbesartan, valsartan and others. Diabetes drugs for treatment include metformin, glimepiride, pioglitazone, and the like. It can be seen that this notice focuses more on hospital antibiotics and commonly used drugs for chronic diseases.